Medicinal Uses of Marijuana and Cannabinoids

Critical Reviews in Plant Sciences

Volumn 35, Issue 5-6, 2016, Pages 378-405

  Grotenhermen, Franjo ^a   Müller Vahl, Kirsten ^b  

^a Nova Institut GmbH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cannabinoids; cannabis; CBD; endocannabinoids; interactions; side effects; THC; therapeutic use

Indexed keywords

EID: 85013066215     PISSN: 07352689     EISSN: 15497836     Source Type: Journal    
DOI: 10.1080/07352689.2016.1265360     Document Type: Review

References (178)

1. Abrams, D. I., Hilton, J. F., Leiser, R. J., Shade, S. B., Elbeik, T. A., Aweeka, F. T., Benowitz, N. L., Bredt, B. M., Kosel, B., Aberg, J. A., Deeks, S. G., Mitchell, T. F., Mulligan, K., Bacchetti, P., McCune, J. M., and Schambelan, M., 2003. Short-term effects of cannabinoids in patients with HIV-1 infection:a randomized, placebo-controlled clinical trial. Ann. Intern. Med. 139(4):258–266.
2. Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., and Petersen, K. L., 2007. Cannabis in painful HIV-associated sensory neuropathy:a randomized placebo-controlled trial. Neurology 68(7):515–521.
3. Ahmedzai, S., Carlyle, D. L., Clader, I. T., and Moran, F., 1983. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br. J. Cancer 48:657–663.
4. Allsop, D., Copeland, J., Lintzeris, N., Dunlop, A., Montebello, M., Sadler, Rivas, G. R., Holland, R. M., Muhleisen, P., Norberg, M. M., Booth, J., and McGregor, I. S., 2014. Nabiximols as an agonist replacement therapy during cannabis withdrawal. JAMA Psychiatry 71(3):281.
5. Aragona, M., Onesti, E., Tomassini, V., Conte, A., Gupta, S., Gilio, F., Pantano, P., Pozzilli, C., and Inghilleri, M., 2009. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis:a double-blind, placebo controlled, crossover study. Clin. Neuropharmacol. 32(1):41–47.
6. Beal, J. E., Olson, R., Laubenstein, L., Morales, J. P., Bellman, P., Yangco, B., Lefkowitz, L., Plasse, T. F., and Shepard, K. V., 1995. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom. Manage. 10(2):89–97.
7. Beaulieu, P., 2006. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can. J. Anaesth. 53(8):769–775.
8. Bergamaschi, M. M., Queiroz, R. H., Chagas, M. H., de Oliveira, D. C., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., Martín-Santos, R., Hallak, J. E., Zuardi, A. W., and Crippa, J. A., 2011. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 36(6):1219–1226.
9. Bergamaschi, M., Queiroz, R., Chagas, M., de Oliveira, D., De Martinis, B., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., Martín-Santos, R., Hallak, J. E., Zuardi, A. W., and Crippa, J. A., 2011. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36(6):1219–1226.
10. Berman, J. S., Symonds, C., and Birch, R., 2004. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion:results of a randomized controlled trial. Pain 112(3):299–306.
11. Blake, D. R., Robson, P., Ho, M., Jubb, R. W., and McCabe, C. S., 2006. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 45(1):50–52.
12. Brisbois, T. D., de Kock, I. H., Watanabe, S. M., Mirhosseini, M., Lamoureux, D. C., Chasen, M., Macdonald, N., Baracos, V. E., and Wismer, W. V., 2011. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients:results of a randomized, double-blind, placebo-controlled pilot trial. Ann. Oncol. 22(9):2086–2093.
13. Buggy, D. J., Toogood, L., Maric, S., Sharpe, P., Lambert, D. G., and Rowbotham, D. J., 2003. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 106(1–2):169–172.
14. Carroll, C. B., Bain, P. G., Teare, L., Liu, X., Joint, C., Wroath, C., Parkin, S. G., Fox, P., Wright, D., Hobart, J., and Zajicek, J. P., 2004. Cannabis for dyskinesia in Parkinson disease:a randomized double-blind crossover study. Neurology 63(7):1245–1250.
15. Chagas, M. H., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E., and Crippa, J. A., 2014. Effects of cannabidiol in the treatment of patients with Parkinson's disease:an exploratory double-blind trial. J. Psychopharmacol. 28(11):1088–1098.
16. Chagas, M., Zuardi, A., Tumas, V., Pena-Pereira, M., Sobreira, E., Bergamaschi, M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E., and Crippa, J. A., 2014. Effects of cannabidiol in the treatment of patients with Parkinson's disease:an exploratory double-blind trial. J. Psychopharmacol. 28(11):1088–1098.
17. Chan, H. S., Correia, J. A., and MacLeod, S. M., 1987. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children:a double-blind, crossover trial. Pediatrics 79:946–952.
18. Chang, A. E., Shiling, D. J., Stillman, R. C., Goldberg, N. H., Seipp, C. A., and Barofsky, I., 1979. Delta-9-tetrahydrocannabinol as an antiemetics in cancer patients receiving high-dose methotrexate. Ann. Intern. Med. 91:819–824.
19. Chang, A. E., Shiling, D. J., Stillman, R. C., Goldberg, N. H., Seipp, C. A., Barofsky, I., and Rosenberg, S. A., 1981. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47:1746–1751.
20. Clifford, D. B., 1983. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann. Neurol. 13:669–671.
21. Collin, C., Davies, P., Mutiboko, I. K., and Ratcliffe, S., for the Sativex Spasticity in MS Study Group. 2007. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol. 14(3):290–296.
22. Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., and Powell, K., 2010. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res. 32(5):451–459.
23. Colls, B. M., Ferry, D. G., Gray, A. J., Harvey, V. J., and McQueen, E. G., 1980. The antiemetic activity of tetrahydrocanabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. N. Z. Med. J. 91:449–451.
24. Consroe, P., Sandyk, R., and Snider, S. R., 1986. Open label evaluation of cannabidiol in dystonic movement disorders. Int. J. Neurosci. 30(4):277–282.
25. Conte, A., Bettolo, C. M., Onesti, E., Frasca, V., Iacovelli, E., Gilio, F., Giacomelli, E., Gabriele, M., Aragona, M., Tomassini, V., Pantano, P., Pozzilli, C., and Inghilleri, M., 2009. Cannabinoid-induced effects on the nociceptive system:a neurophysiological study in patients with secondary progressive multiple sclerosis. Eur. J. Pain. 13(5):472–477.
26. Corey-Bloom, J., Wolfson, T., Gamst, A., Jin, S., Marcotte, T., Bentley, H., and Gouaux, B., 2012. Smoked cannabis for spasticity in multiple sclerosis:a randomized, placebo-controlled trial. CMAJ 184(10):1143–1150.
27. Côté, M., Trudel, M., Wang, C., and Fortin, A., 2015. Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers:a randomized double-blind placebo-controlled trial. Ann. Otol. Rhinol. Laryngol. [in press].
28. Crawford, S. M., and Buckman, R., 1986. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum:a double blind study. Med. Oncol. Tumor Pharmacother. 3:39–42.
29. Crippa, J. A., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Santos Filho, A., Freitas-Ferrari, M. C., McGuire, P. K., Zuardi, A. W., Busatto, G. F., and Hallak, J. E., 2011. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder:a preliminary report. J. Psychopharmacol. 25(1):121–130.
30. Crippa, J., Derenusson, G., Ferrari, T., Wichert-Ana, L., Duran, F., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Santos Filho, A., Freitas-Ferrari, M. C., McGuire, P. K., Zuardi, A. W., Busatto, G. F., and Hallak, J. E., 2011. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder:a preliminary report. J. Psychopharmacol. 25(1):121–130.
31. Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., and Mechoulam, R., 1980. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21(3):175–185.
32. Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., and Mechoulam, R., 1980. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21(3):175–185.
33. Dalzell, A. M., Bartlett, H., and Lilleyman, J. S., 1986. Nabilone:an alternative antiemetic for cancer chemotherapy. Arch. Dis. Child. 61:502–505.
34. Das, R., Kamboj, S., Ramadas, M., Yogan, K., Gupta, V., Redman, E., Curran, H. V., and Morgan, C. J., 2013. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology 226(4):781–792.
35. Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., Wong, M., Tilton, N., Bruno, P., Bluvstein, J., Hedlund, J., Kamens, R., Maclean, J., Nangia, S., Singhal, N. S., Wilson, C. A., Patel, A., and Cilio, M. R., 2015. Cannabidiol in patients with treatment-resistant epilepsy:an open-label interventional trial. Lancet Neurol. [in press].
36. D'Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., and Krystal, J. H., 2005. Delta-9-tetrahydrocannabinol effects in schizophrenia:implications for cognition, psychosis, and addiction. Biol. Psychiatry 57(6):594–608.
37. Duran, M., Pérez, E., Abanades, S., Vidal, X., Saura, C., Majem, M., Arriola, E., Rabanal, M., Pastor, A., Farré, M., Rams, N., Laporte, J. R., and Capellà, D., 2010. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br. J. Clin. Pharmacol. 70(5):656–663.
38. Einhorn, L. H., Nagy, C., Furnas, B., and Williams, S. D., 1981. Nabilone:an effective antiemetic in patients receiving cancer chemotherapy. J. Clin. Pharmacol. 21(8–9 Suppl):64–69.
39. Ellis, R. J., Toperoff, W., Vaida, F., van den Brande, G., Gonzales, J., Gouaux, B., Bentley, H., and Atkinson, J. H., 2009. Smoked medicinal cannabis for neuropathic pain in HIV:a randomized, crossover clinical trial. Neuropsychopharmacology 34(3):672–680.
40. ElSohly, M. 2016, November. My Journey with Cannabis:Past, Present and Future. Presentation at the SACM Conference, Basel, Switzerland.
41. Engels, F. K., de Jong, F. A., Sparreboom, A., Mathot, R. A., Loos, W. J., Kitzen, J. J., de Bruijn, P., Verweij, J., and Mathijssen, R. H., 2007. Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist 12(3):291–300.
42. Englund, A., Atakan, Z., Kralj, A., Tunstall, N., Murray, R., and Morrison, P., 2015. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers:a placebo-controlled, double-blind, crossover pilot trial. J. Psychopharmacol. [in press].
43. Esfandyari, T., Camilleri, M., Busciglio, I., Burton, D., Baxter, K., and Zinsmeister, A. R., 2007. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans:a randomized, placebo-controlled study. Am. J. Physiol. Gastrointest. Liver. Physiol. 293(1):137–145.
44. Esfandyari, T., Camilleri, M., Ferber, I., Burton, D., Baxter, K., and Zinsmeister, A. R., 2006. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects:a randomized, placebo-controlled study. Neurogastroenterol. Motil. 18(9):831–838.
45. Fankhauser, M., 2003. Haschisch als Medikament:Zur Bedeutung von cannabis sativa in der westlichen Medizin. SGGP, Schweizerischer Apothekerverein, Liebefeld (Schweiz).
46. Fox, P., Bain, P. G., Glickman, S., Carroll, C., and Zajicek, J., 2004. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 62(7):1105–1109.
47. Fox, S. H., Kellett, M., Moore, A. P., Crossman, A. R., and Brotchie, J. M., 2002. Randomized, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov. Disord. 17(1):145–149.
48. Frank, B., Serpell, M. G., Hughes, J., Matthews, J. N., and Kapur, D., 2008. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain:randomized, crossover, double blind study. BMJ 336(7637):199–201.
49. Freeman, R. M., Adekanmi, O., Waterfield, M. R., Waterfield, A. E., Wright, D., and Zajicek, J., 2006. The effect of cannabis on urge incontinence in patients with multiple sclerosis:a multicentre, randomized placebo-controlled trial (CAMS-LUTS). Int. Urogynecol. J. Pelvic. Floor. Dysfunct. 17(6):636–641.
50. Frytak, S., Moertel, C. G., O'Fallon, J. R., Rubin, J., Creagan, E. T., and O'Connnell, M. J., 1979. Delta-9-tetrahydrocannabinol as an antiemetics for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann. Intern. Med. 91:825–830.
51. Gaoni, Y., and Mechoulam, R., 1964. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86:1646–1647.
52. George, M., Pejovic, M. H., Thuaire, M., Kramar, A., and Wolff, J. P., 1983. Randomized comparative trial of a new anti-emetic:nabilone, in cancer patients treated with cisplatin. Biomed. Pharmacother. 37:24–27.
53. Gralla, R. J., Tyson, L. B., Bordin, L. A., Clark, R. A., Kelsen, D. P., and Kris, M. G., 1984. Antiemetic therapy:a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treat. Rep. 68:163–172.
54. Grant, J. E., Odlaug, B. L., Chamberlain, S. R., and Kim, S. W., 2011. Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania:a pilot study. Psychopharmacology (Berl). 218(3):493–502.
55. Grant, J. E., Odlaug, B. L., Chamberlain, S. R., and Kim, S. W., 2011. Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania:a pilot study. Psychopharmacology (Berl). 218(3):493–502.
56. Greenberg, H. S., Werness, S. A. S., Pugh, J. E., Andrus, R. O., Anderson, D. J., and Domino, E. F., 1994. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin. Pharmacol. Ther. 55:324–328.
57. Grotenhermen, F., 2005. Cannabinoids. Curr. Drug. Targets. CNS. Neurol. Disord. 4(5):507–530.
58. Grotenhermen, F., 2014. Non-psychological adverse effects. In:Handbook of Cannabis. pp. 674–691. Pertwee, R., Ed., Oxford University Press, Oxford.
59. Grotenhermen, F., Berger, M., and Gebhardt, K., 2015. Cannabidiol (CBD):Ein cannabishaltiges Compendium. Nachtschatten Verlag, Solothurn (Schweiz).
60. Grotenhermen, F. and Müller-Vahl, K. 2012. The therapeutic potential of cannabis and cannabinoids. Dtsch. Arztebl. Int. 109(29-30):495-501.
61. Hagenbach, U., Luz, S., Ghafoor, N., Berger, J. M., Grotenhermen, F., Brenneisen, R., and Mäder, M., 2007. The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord. 45(8):551–562.
62. Haney, M., Gunderson, E. W., Rabkin, J., Hart, C. L., Vosburg, S. K., Comer, S. D., and Foltin, R. W., 2007. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J. Acquir. Immune. Defic. Syndr. 45(5):545–554.
63. Haney, M., Rabkin, J., Gunderson, E., and Foltin, R. W., 2005. Dronabinol and marijuana in HIV(+) marijuana smokers:acute effects on caloric intake and mood. Psychopharmacology (Berl) 181(1):170–178.
64. 9-THC on human spasticity. Clinic. Pharmacol. Ther. 39:198.
65. Hazekamp, A., Ware, M. A., Muller-Vahl, K. R., Abrams, D., and Grotenhermen, F., 2013. The medicinal use of cannabis and cannabinoids–an international cross-sectional survey on administration forms. J. Psychoactive Drugs 45(3):199–210.
66. Herman, T. S., Einhorn, L. H., Jones, S. E., Nagy, C., Chester, A. B., and Dean, J. C., 1979. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N. Engl. J. Med. 300:1295–1297.
67. Hindocha, C., Freeman, T. P., Schafer, G., Gardener, C., Das, R. K., Morgan, C. J., and Curran, H. V., 2015. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition:a randomized, double-blind, placebo-controlled study in cannabis users. Eur. Neuropsychopharmacol. 25(3):325–334.
68. Holdcroft, A., Maze, M., Dore, C., Tebbs, S., and Thompson, S., 2006. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 104(5):1040–1046.
69. Holdcroft, A., Maze, M., Dore, C., Tebbs, S., and Thompson, S., 2006. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 104(5):1040–1046.
70. Holdcroft, A., Smith, M., Jacklin, A., Hodgson, H., Smith, B., Newton, M., and Evans, F., 1997. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 52:483–488.
71. Hollister, L. E., 1999. Interactions of marihuana and Δ9-THC with other drugs. In:Marihuana and Medicine. pp. 273–277. Nahas, G., Sutin, K. M., Harvey, D. J., and Agurell, S., Eds., Humana Press, Totowa, NJ.
72. Hutcheon, A. W., Palmer, J. B., Soukop, M., Cunningham, D., McArdle, C., and Welsh, J., 1983. A randomized multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with ychlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur. J. Cancer. Clin. Oncol. 19:1087–1090.
73. Issa, M., Narang, S., Jamison, R., Michna, E., Edwards, R., Penetar, D., and Wasan, A. D., 2014. The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain. Clin. J. Pain. 30(6):472–478.
74. Jain, A. K., Ryan, J. R., McMahon, F. G., and Smith, G., 1981. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J. Clin. Pharmacol. 21(suppl 8–9):320–326.
75. Jatoi, A., Windschitl, H. E., Loprinzi, C. L., Sloan, J. A., Dakhil, S. R., Mailliard, J. A., Pundaleeka, S., Kardinal, C. G., Fitch, T. R., Krook, J. E., Novotny, P. J., and Christensen, B., 2002. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia:a North Central Cancer Treatment Group study. J. Clin. Oncol. 20(2):567–573.
76. Jetly, R., Heber, A., Fraser, G., and Boisvert, D., 2015. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares:a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology 51:585–588.
77. Jiang, R., Yamaori, S., Okamoto, Y., Yamamoto, I., and Watanabe, K., 2013. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug. Metab. Pharmacokinet. 28(4):332–338.
78. Jochimsen, P. R., Lawton, R. L., VerSteeg, K., and Noyes, Jr.R., 1978. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clin. Pharmacol. Ther. 24:223–227.
79. Johansson, R., Kilkku, P., and Groenroos, M., 1982. A double-blind, controlled trial of nabilone vs prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat. Rev. 9:25–33.
80. Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., and Fallon, M. T., 2010. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J. Pain Symptom. Manage. 39(2):167–179.
81. Johnson, J. R., Lossignol, D., Burnell-Nugent, M., and Fallon, M. T., 2013. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J. Pain Symptom. Manage. 46(2):207–218.
82. Jones, S. E., Durant, J. R., Greco, F. A., and Robertone, A., 1982. A multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting. Cancer Treat. Rev. 9:45–48.
83. Karst, M., Salim, K., Burstein, S., Conrad, I., Hoy, L., and Schneider, U., 2003. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain:a randomized controlled trial. JAMA 290(13):1757–1762.
84. Katona, S., Kaminski, E., Sanders, H., and Zajicek, J., 2005. Cannabinoid influence on cytokine profile in multiple sclerosis. Clin. Exp. Immunol. 140(3):580–585.
85. Kavi, R. B., De Ridder, D., Constantinescu, C. S., Stott, C. G., and Fowler, C. J., 2010. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult. Scler. 16(11):1349–1359.
86. Killestein, J., Hoogervorst, E. L., Reif, M., Kalkers, N. F., Van Loenen, A. C., Staats, P. G., Gorter, R. W., Uitdehaag, B. M., and Polman, C. H., 2002. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 58(9):1404–1407.
87. Klooker, T., Leliefeld, K., Van Den Wijngaard, R., and Boeckxstaens, G., 2011. The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients. Neurogastroenterol. Motil. 23(1):30–e2.
88. Kluin-Nelemans, J. C., Nelemans, F. A., Meuwissen, O. J. A. T. h., and Maes, R. A. A., 1979. Δ9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo. N. Engl. J. Med. 21:338–340.
89. Kosel, B. W., Aweeka, F. T., Benowitz, N. L., Shade, S. B., Hilton, J. F., Lizak, P. S., and Abrams, D. I., 2002. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 16(4):543–550.
90. Kraft, B., Frickey, N. A., Kaufmann, R. M., Reif, M., Frey, R., Gustorff, B., and Kress, H. G., 2008. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 109(1):101–110.
91. Lane, M., Vogel, C. L., Ferguson, J., Krasnow, S., Saiers, J. L., and Hamm, J., 1991. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J. Pain Symptom. Manage. 6:352–359.
92. Langford, R. M., Mares, J., Novotna, A., Vachova, M., Novakova, I., Notcutt, W., and Ratcliffe, S., 2013. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J. Neurol. 260(4):984–997.
93. Levin, F., Mariani, J., Brooks, D., Pavlicova, M., Cheng, W., and Nunes, E., 2011. Dronabinol for the treatment of cannabis dependence:a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 116(1–3):142–150.
94. Levitt, M., 1982. Nabilone vs placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treat. Rev. 9(suppl B):49–53.
95. Levitt, M., Faiman, C., Hawks, R., and Wilson, A., 1984. Randomized double blind comparison of delta-9-tetrahydroicannabinol (THC) and marijuana as chemotherapy antiemetics. Proc. Am. Med. Soc. Clin. Onc. 3:91.
96. Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., and Koethe, D., 2012. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry. 20:(2):e94.
97. Leweke, F., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C., Hoyer, C., Klosterkötter, J., Hellmich, M., and Koethe, D., 2012. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry. 2(3):e94.
98. Lindstrom, P., Lindblom, U., and Boreus, L., 1992. Lack of effect of cannabidiol in sustained neuropathia. Paper presented at '87 International Conference on Cannabis, Melbourne, September 2–4, 1987. Cited from:Consroe, P., and Sandyk, R. Potential role of cannabinoids for therapy of neurological disorders. In:Marijuana/Cannabinoids. Neurobiology and Neurophysiology. pp. 459–524. Murphy, L., and Bartke, A., Eds., CRC Press, Boca Raton, FL.
99. Loewe, S., 1950. Cannabiswirkstoffe und Pharmakologie der Cannabinole. Arch. Exp. Pathol. Pharmakol. 211:175–193.
100. Lynch, M., Cesar-Rittenberg, P., and Hohmann, A., 2014. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J. Pain Symptom. Manage. 47(1):166–173.
101. Maccarrone, M., Bab, I., Bíró, T., Cabral, G. A., Dey, S. K., Di Marzo, V., Konje, J. C., Kunos, G., Mechoulam, R., Pacher, P., Sharkey, K. A., and Zimmer, A., 2015. Endocannabinoid signaling at the periphery:50 years after THC. Trends. Pharmacol. Sci. 36(5):277–296.
102. Martyn, C. N., Illis, L. S., and Thom, J., 1995. Nabilone in the treatment of multiple sclerosis. Lancet. 345:579.
103. Maurer, M., Henn, V., Dittrich, A., and Hofmann, A., 1990. Delta-9-THC shows antispastic and analgesic effects in a single case double blind trial. Eur. Arch. Psychiatry Clin. Neurosci. 240:1–4.
104. McCabe, M., Smith, F. P., Goldberg, D., Macdonald, J., Woolley, P. V., and Warren, R., 1988. Efficacy of tetrahydrocannabinol in patients refractory to standard anti-emetic therapy. Invest. New Drugs. 6:243–246.
105. Mechoulam, R., and Parker, L. A., 2013. The endocannabinoid system and the brain. Annu. Rev. Psychol. 64:21–47.
106. Meiri, E., Jhangiani, H., Vredenburgh, J. J., Barbato, L. M., Carter, F. J., Yang, H. M., and Baranowski, V., 2007. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr. Med. Res. Opin. 23(3):533–543.
107. Merritt, J. C., Crawford, W. J., Alexander, P. C., Anduze, A. L., and Gelbart, S. S., 1980. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 87(3):222–228.
108. Merritt, J. C., Olsen, J. L., Armstrong, J. R., and McKinnon, S. M., 1981. Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas. J. Pharm. Pharmacol. 33(1):40–41.
109. Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., and Lewis, G., 2007. Cannabis use and risk of psychotic or affective mental health outcomes:a systematic review. Lancet 370(9584):319–328.
110. Mueller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., and Emrich, H. M., 2003. Delta-9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome:a 6-week randomized trial. J. Clin. Psychiatry 64(4):459–465.
111. Müller-Vahl, K. R., Schneider, U., Koblenz, A., Jobges, M., Kolbe, H., Daldrup, T., and Emrich, H. M., 2002. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC):a randomized crossover trial. Pharmacopsychiatry 35(2):57–61.
112. Müller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., and Emrich, H. M., 2003. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome:a 6-week randomized trial. J. Clin. Psychiatry 64(4):459–465.
113. Naef, M., Curatolo, M., Petersen-Felix, S., Arendt-Nielsen, L., Zbinden, A., and Brenneisen, R., 2003. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105(1–2):79–88.
114. Naftali, T., Bar-Lev Schleider, L., Dotan, I., Lansky, E., Sklerovsky Benjaminov, F., and Konikoff, F., 2013. Cannabis induces a clinical response in patients with crohn's disease:a prospective placebo-controlled study. Clin. Gastroenterol. Hepatol. 11(10):1276–1280.
115. Narang, S., Gibson, D., Wasan, A. D., Ross, E. L., Michna, E., Nedeljkovic, S. S., and Jamison, R. N., 2008. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J. Pain. 9(3):254–264.
116. Neidhart, J. A., Gagen, M. M., Wilson, H. E., and Young, D. C., 1981. Comparative trial of the antiemetic effects of THC and haloperidol. J. Clin. Pharmacol. 21:38–42.
117. Niederle, N., Schutte, J., and Schmidt, C. G., 1986. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin. Wochenschr. 64:362–365.
118. Niiranen, A., and Mattson, K., 1985. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am. J. Clin. Oncol. 8:336–340.
119. Notcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmons, S., and Sansom, C., 2004. Initial experiences with medicinal extracts of cannabis for chronic pain:results from 34 'N of 1' studies. Anaesthesia 59(5):440–452.
120. Notcutt. W., Langford, R., Davies, P., Ratcliffe, S., and Potts, R., 2012. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Mult. Scler. 18(2):219–228.
121. Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., Rossi, P., Ambler, Z., Stelmasiak, Z., Erdmann, A., Montalban, X., Klimek, A., and Davies, P., 2011. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 18(9):1122–1131.
122. Noyes, R., Brunk, S. F., Baram, D. A., and Canter, A., 1975. Analgesic effects of delta-9-THC. J. Clin. Pharmacol. 15:139–143.
123. Noyes, R., Brunk, S. T., Avery, D. H., and Canter, A., 1975. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin. Pharmacol. Ther. 18:84–89.
124. Nurmikko, T. J., Serpell, M. G., Hoggart, B., Toomey, P. J., Morlion, B. J., and Haines, D., 2007. Sativex successfully treats neuropathic pain characterised by allodynia:a randomized, double-blind, placebo-controlled clinical trial. Pain 133(1–3):210–220.
125. Orr, L. E., McKernan, J. F., and Bloome, B., 1980. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch. Intern. Med. 140:1431–1433.
126. Pertwee, R., 2014. Handbook of Cannabis. Oxford University Press, Oxford.
127. Pertwee, R. G., 2010. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem. 17(14):1360–1381.
128. 9-tetrahydrocannabinol. J. Clin. Pharmacol. (Suppl 21):413–416.
129. Pickering, E. E., Semple, S. J., Nazir, M. S., Murphy, K., Snow, T. M., Cummin, A. R., Moosavi, S., Guz, A., and Holdcroft, A., 2011. Cannabinoid effects on ventilation and breathlessness:a pilot study of efficacy and safety. Chron. Respir. Dis. 8(2):109–118.
130. Pinsger, M., Schimetta, W., Volc, D., Hiermann, E., Riederer, F., and Polz, W., 2006. [Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain—a randomized controlled trial.] [Artikel in deutsch]. Wien. Klin. Wochenschr. 118(11–12):327–335.
131. Pomeroy, M., Fennelly, J. J., and Towers, M., 1986. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother. Pharmacol. 17:285–288.
132. Portenoy, R., Ganae-Motan, E., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S., McQuade, R., Wright, S., and Fallon, M. T., 2012. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain:a randomized, placebo-controlled, graded-dose trial. J. Pain. 13(5):438–449.
133. Raft, D., Gregg, J., Ghia, J., and Harris, L., 1977. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain:psychological correlates of the analgesic response. Clin. Pharmacol. Ther. 21:26–33.
134. Redmond, W. J., Goffaux, P., Potvin, S., and Marchand, S., 2008. Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. Curr. Med. Res. Opin. 24(4):1017–1024.
135. Regelson, W., Butler, J. R., Schulz, J., Kirk, T., Peek, L., Green, M. L., and Zalis, M. O., 1976. Delta-9-tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In:Pharmacology of Marihuana. 2. pp. 763–776. Braude, M. C., and Szara, S., Eds., Raven Press, New York.
136. Riggs, P. K., Vaida, F., Rossi, S. S., Sorkin, L. S., Gouaux, B., Grant, I., and Ellis, R. J., 2012. A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain Res. 1431:46–52.
137. Rintala, D. H., Fiess, R. N., Tan, G., Holmes, S. A., and Bruel, B. M., 2010. Effect of dronabinol on central neuropathic pain after spinal cord injury:a pilot study. Am. J. Phys. Med. Rehabil. 89(10):840–848.
138. Roberts, J. D., Gennings, C., and Shih, M., 2006. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur. J. Pharmacol. 530(1–2):54–58.
139. Rog, D. J., Nurmikko, T. J., Friede, T., and Young, C. A., 2005. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65(6):812–819.
140. Sallan, S. E., Cronin, C., Zelen, M., and Zinberg, N. E., 1980. Antiemetics in patients receiving chemotherapy for cancer. A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N. Engl. J. Med. 302:135–138.
141. Sallan, S. E., Zinberg, N. E., and Frei, E., 1975. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N. Engl. J. Med. 293:795–797.
142. Schwarcz, G., and Karajgi, B., 2010. Improvement in refractory psychosis with dronabinol:four case reports. J. Clin. Psychiatry 71(11):1552–1553.
143. Seeling, W., Kneer, L., Buchele, B., Gschwend, J. E., Maier, L., Nett, C., Simmet, T., Steffen, P., Schneider, M., and Rockemann, M., 2006. [(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain.] [Article in German]. Anaesthesist 55(4):391–400.
144. Selvarajah, D., Gandhi, R., Emery, C. J., and Tesfaye, S., 2010. Randomized placebo controlled double blind clinical trial of cannabis based medicinal product (sativex) in painful diabetic neuropathy:depression is a major confounding factor. Diabetes Care 33(1):128–130.
145. Serpell, M., Ratcliffe, S., Hovorka, J., Schofield, M., Taylor, L., and Lauder, H., 2014. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur. J. Pain 18(7):999–1012.
146. Sieradzan, K. A., Fox, S. H., Hill, M., Dick, J. P., Crossman, A. R., and Brotchie, J. M., 2001. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease:a pilot study. Neurology 57(11):2108–2111.
147. Skrabek, R. Q., Galimova, L., Ethans, K., and Perry, D., 2008. Nabilone for the treatment of pain in fibromyalgia. J. Pain 9(2):164–173.
148. Staquet, M., Gantt, C., and Machin, D., 1978. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin. Pharmacol. Ther. 23:397–401.
149. Steele, N., Gralla, R. J., Braun, Jr. D. W., and Young, C. W., 1980. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat. Rep. 64:219–224.
150. Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., Ko, Y. D., Schnelle, M., Reif, M., and Cerny, T., 2006. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome:a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-in-Cachexia-Study-Group. J. Clin. Oncol. 24(21):3394–3400.
151. Struwe, M., Kaempfer, S. H., Geiger, C. J., Pavia, A. T., Plasse, T. F., Shepard, K. V., Ries, K., and Evans, T. G., 1993. Effect of dronabinol on nutritional status in HIV infection. Ann. Pharmacother. 27(7–8):827–831.
152. Svendsen, K. B., Jensen, T. S., and Bach, F. W., 2004. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomized double blind placebo controlled crossover trial. BMJ 329(7460):253.
153. Tomida, I., Azuara-Blanco, A., House, H., Flint, M., Pertwee, R. G., 2006. Robson, P. J. Effect of sublingual application of cannabinoids on intraocular pressure:a pilot study. J. Glaucoma. 15(5):349–353.
154. Tomida, I., Azuara-Blanco, A., House, H., Flint, M., Pertwee, R. G., and Robson, P. J., 2006. Effect of sublingual application of cannabinoids on intraocular pressure:a pilot study. J. Glaucoma. 15(5):349–353.
155. Ungerleider, J. T., Andrysiak, T., Fairbanks, L., Goodnight, J., Sarna, G., and Jamison, K., 1982. Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine. Cancer 50:636–645.
156. 9-THC in the treatment of spasticity associated with multiple sclerosis. Adv. Alcohol. Subst. Abuse. 7:39–50.
157. van den Elsen, G. A., Ahmed, A. I., Verkes, R. J., Kramers, C., Feuth, T., Rosenberg, P. B., van der Marck, M. A., and Olde Rikkert, M. G., 2015. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia:a randomized controlled trial. Neurology 84(23):2338–2346.
158. Vandrey, R. G., Budney, A. J., Hughes, J. R., Liguori, A., 2008. A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. Drug. Alcohol. Depend. 92(1–3):48–54.
159. Vaney, C., Heinzel-Gutenbrunner, M., Jobin, P., Tschopp, F., Gattlen, B., Hagen, U., Schnelle, M., and Reif, M., 2004. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis:a randomized, double-blind, placebo-controlled, crossover study. Mult. Scler. 10(4):417–424.
160. Wada, J. K., Bogdon, D. L., Gunnell, J. C., Hum, G. J., Gota, C. H., and Rieth, T. E., 1982. Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treat. Rev. 9(Suppl B):39–44.
161. Wade, D. T., Makela, P. M., House, H., Bateman, C., and Robson, P., 2006. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler. 12(5):639–645.
162. Wade, D. T., Makela, P., Robson, P., House, H., and Bateman, C., 2004. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. 10(4):434–441.
163. Wade, D. T., Robson, P., House, H., Makela, P., and Aram, J., 2003. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17:18–26.
164. Wade, D. T., Robson, P., House, H., Makela, P., Aram, J., 2003. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17:18–26.
165. Wade, D. T., Robson, P., House, H., Makela, P., and Aram, J., 2003. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17:18–26.
166. Wallace, M. S., Marcotte, T. D., Umlauf, A., Gouaux, B., and Atkinson, J. H., 2015. Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. J. Pain. 16(7):616–627.
167. Wallace, M., Schulteis, G., Atkinson, J. H., Wolfson, T., Lazzaretto, D., Bentley, H., Gouaux, B., and Abramson, I., 2007. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 107(5):785–796.
168. Ware, M. A., Ducruet, T., and Robinson, A. R., 2006. Evaluation of herbal cannabis characteristics by medical users:a randomized trial. Harm Reduct J. 3(1):32.
169. Ware, M. A., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T., Gamsa, A., Bennett, G. J., and Collet, J. P., 2010. Smoked cannabis for chronic neuropathic pain:a randomized controlled trial. CMAJ 182(14):E694–E701.
170. Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., and Kleijnen, J., 2015. Cannabinoids for medical use:a systematic review and meta-analysis. JAMA 313(24):2456–2473.
171. Wilsey, B., Marcotte, T., Deutsch, R., Gouaux, B., Sakai, S., and Donaghe, H., 2013. Low-dose vaporized cannabis significantly improves neuropathic pain. J. Pain 14(2):136–148.
172. Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B., and Fishman, S., 2008. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J. Pain 9(6):506–521.
173. Wissel, J., Haydn, T., Müller, J., Brenneis, C., Berger, T., Poewe, W., and Schelosky, L. D., 2006. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain:a double-blind placebo-controlled cross-over trial. J. Neurol. 253(10):1337–1341.
174. Wong, B. S., Camilleri, M., Busciglio, I., Carlson, P., Szarka, L. A., Burton, D., and Zinsmeister, A. R., 2011. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology 141(5):1638–1647.
175. Wong, B., Camilleri, M., Busciglio, I., Carlson, P., Szarka, L., Burton, D., and Zinsmeister, A. R., 2011. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology 141(5):1638–1647.
176. Wong, B., Camilleri, M., Busciglio, I., Carlson, P., Szarka, L., Burton, D., and Zinsmeister, A. R., 2012. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol Motil. 24(4):358–e169.
177. Zajicek, J., Ball, S., Wright, D., Vickery, J., Nunn, A., and Miller, D., 2013. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID):a randomized, placebo-controlled trial. Lancet Neurol. 12(9):857–865.
178. Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., and Thompson, A., on behalf of the UK MS Research Group. 2003. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study):multicentre randomized placebo-controlled trial. Lancet 362(9385):1517–1526.